FeesSafety
Pluang+

Rocket Lab delays Neutron rocket debut to 2027, impacting revenue and profitability outlook.

Market News
08 Nov 2026, 20:08 WIB
Tokenpost
View Source
Bearish
Rocket Lab delays Neutron rocket debut to 2027, impacting revenue and profitability outlook.

Rocket Lab has delayed the debut of its Neutron reusable medium-class rocket to 2027 due to a setback with the first-stage tank. This delay increases the company's reliance on its Electron rocket launches and Space Systems division, putting its path to positive EBITDA at risk. Wall Street expects Rocket Lab to report $257.18 million in revenue and a loss of 2 cents per share in its upcoming third-quarter report. Investors are closely watching for updates on Neutron's development and customer demand as the company faces these challenges.

Rocket Lab's Q3 earnings preview is the subject, with Pluang market data providing context. As of Nov 09, 2026 01:02 WIB, 8 of 50 major cryptocurrencies rose while 40 fell. Notable movers include XTZ at Rp4.567 (-4.32%), ZIL at Rp30 (-4.27%), and KSM at Rp56.574 (-4.17%).

More News

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
Bullish
2 hours ago
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
2 hours ago
Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...

Others
Neutral
3 hours ago
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...

Market News
Bullish
3 hours ago
$1,000 invested in ADP 10 years ago grew to $4,147 with dividends reinvested, outpacing the S&P 500.

$1,000 invested in ADP 10 years ago grew to $4,147 with dividends reinvested, outpacing the S&P 500.

ADP's dual income from payroll fees and investing client payroll funds helped it grow steadily over the past decade. A $1,000 investment in ADP in 2016 would be worth $4,147 today with dividends reinvested, outperforming the S&P 500's 243% return. De...

Market News
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App